Regulation 5 Fee for scientific advice: classification of a medicinal product
The fee payable by a person with whom the licensing authority holds a meeting to provide scientific advice in connection with the classification of a relevant medicinal product, is—
F1£8,758, if the advice relates to a product which, if reclassified, will be available on general sale; and
F2£8,758, if the advice relates to a product which, if reclassified, will be available without a prescription from a pharmacy.
For the purposes of this regulation, a product is on general sale if it is a medicinal product subject to general sale within the meaning of regulation 5(1) of the Human Medicines Regulations (classification of medicinal products for general sale).
Annotations
Textual amendments
- F1
Sum in reg. 5(1)(a) substituted (1.4.2025) by The Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2025 (S.I. 2025/317), regs. 1(2), 5(a)
- F2
Sum in reg. 5(1)(b) substituted (1.4.2025) by The Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2025 (S.I. 2025/317), regs. 1(2), 5(b)